| 7.26 0.07 (0.97%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.76 | 1-year : | 14.83 |
| Resists | First : | 9.21 | Second : | 12.69 |
| Pivot price | 6.3  |
|||
| Supports | First : | 3.57 | Second : | 2.97 |
| MAs | MA(5) : | 8.6  |
MA(20) : | 5.69 |
| MA(100) : | 4.39 |
MA(250) : | 4.73 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 48 |
D(3) : | 63.8 |
| RSI | RSI(14): 58.1 |
|||
| 52-week | High : | 12.69 | Low : | 3.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MOLN ] has closed below upper band by 38.5%. Bollinger Bands are 672.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.61 - 7.65 | 7.65 - 7.69 |
| Low: | 7.15 - 7.19 | 7.19 - 7.23 |
| Close: | 7.2 - 7.26 | 7.26 - 7.32 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Mon, 17 Jun 2024
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit - Yahoo Finance
Fri, 14 Jun 2024
Molecular Partners' New Therapy Shows AML Treatment Promise - TipRanks.com - TipRanks
Fri, 14 Jun 2024
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 - StockTitan
Wed, 12 Jun 2024
Molecular Partners (NASDAQ:MOLN) Trading 13.4% Higher - MarketBeat
Tue, 11 Jun 2024
Molecular Partners Unveils Promising Cancer Therapy - TipRanks.com - TipRanks
Tue, 11 Jun 2024
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 49 (K) |
| Shares Short P.Month | 56 (K) |
| EPS | -2.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.13 |
| Profit Margin | 0 % |
| Operating Margin | -579.2 % |
| Return on Assets (ttm) | -18 % |
| Return on Equity (ttm) | -30 % |
| Qtrly Rev. Growth | -10.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.2 |
| EBITDA (p.s.) | -1.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -3.62 |
| PEG Ratio | 0 |
| Price to Book value | 1.41 |
| Price to Sales | 35.79 |
| Price to Cash Flow | -4.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|